Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
10 Moving Design Frill for Summer 2023 - 2Grasping the Commencement of Criminal Cases: An Extensive Outline
- 3Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- 4Figure out How to Forestall Tooth Staining
- 5Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- France bans Muslim gathering citing risk to participants
- The race is on to turn your body into a GLP-1 factory
- NASA set for first crewed moon return in over half a century
- Sintana Energy flags major resource upgrade at Namibia oil discovery
- Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- What to watch for in weight loss drugs in 2026
